Implications for selectivity of 3,4-diarylquinolinones as p38αMAP kinase inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 4, 2008, Pages 1431-1435

  Peifer, Christian ^a   Urich, Robert ^a   Schattel, Verena ^a   Abadleh, Mohammed ^a   Röttig, Marc ^a   Kohlbacher, Oliver ^a   Laufer, Stefan ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Inhibitors; p38MAP kinase; Selectivity

Indexed keywords

3 (4 FLUOROPHENYL) 4 PYRIDIN 4 YLQUINOLIN 2(1 H) ONE; 4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIN DEPENDENT KINASE 1; EXTRACELLULAR SIGNAL REGULATED KINASE 8; ISOENZYME; ISOPROTEIN; ISOXAZOLE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 11; MITOGEN ACTIVATED PROTEIN KINASE 12; MITOGEN ACTIVATED PROTEIN KINASE 13; MITOGEN ACTIVATED PROTEIN KINASE 14; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; PROTEIN KINASE; PROTEIN KINASE D; PROTEIN KINASE LCK; QUINOLINE DERIVATIVE; QUINOLONE; STRESS ACTIVATED PROTEIN KINASE 1; UNCLASSIFIED DRUG;

ALDOL REACTION; ARTICLE; BINDING KINETICS; DRUG BINDING; DRUG SELECTIVITY; DRUG SPECIFICITY; ENZYME INHIBITION; ENZYME ISOLATION; IC 50; PROTEIN FAMILY; SEQUENCE HOMOLOGY; STRUCTURE ACTIVITY RELATION; X RAY ANALYSIS;

ADENOSINE TRIPHOSPHATE; BINDING SITES; BIPHENYL COMPOUNDS; HUMANS; HYDROGEN BONDING; INHIBITORY CONCENTRATION 50; ISOENZYMES; MITOGEN-ACTIVATED PROTEIN KINASE 14; MITOGEN-ACTIVATED PROTEIN KINASES; MODELS, MOLECULAR; PROTEIN KINASE INHIBITORS; QUINOLONES; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY;

EID: 38949169846     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.12.073     Document Type: Article

References (27)

1. Richards M.L. Curr. Top. Med. Chem. 6 (2006) 75
2. Boldt S., and Kolch W. Curr. Pharm. Des. 10 (2004) 1885
3. Scapin G. Drug Discovery Today 7 (2002) 601
4. Peifer C., Kinkel K., Abadleh M., Schollmeyer D., and Laufer S. J. Med. Chem. 50 (2007) 1213
5. Bain J., McLauchlan H., Elliott M., and Cohen P. Biochem. J. 371 (2003) 199
6. Bain J., Plater L., Elliott M., Shpiro N., Hastia J., McLauchlan H., Klevernic I., Arthur S., Alessi D., and Cohen P. Biochem. J. 408 (2007) 297
7. Davies S.P., Reddy H., Caivano M., and Cohen P. Biochem. J. 351 (2000) 95
8. Skaalhegg B.S., Funderud A., Henanger H., Hatledal H., Tilahun T., Larsen A.C., Kvissel A.K., Eikvar S., and Oerstavik S. Curr. Drug Targets 6 (2005) 655
9. Rozengurt E., Rey O., and Waldron R.T. J. Biol. Chem. 280 (2005) 13205
10. Kamens J.S., Ratnofsky S.E., and Hirst G.C. Curr. Opin. Investig. Drugs 2 (2001) 1213
11. Knippschild U., Wolff S., Giamas G., Brockschmidt C., Wittau M., Wuerl P.U., Eismann T., and Stoeter M. Onkologie 28 (2005) 508
12. Godl K., Wissing J., Kurtenbach A., Habenberger P., Blencke S., Gutbrod H., Salassidis K., Stein-Gerlach M., Missio A., Cotten M., and Daub H. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 15434
13. Keen N., and Taylor S. Nat. Rev. Cancer 4 (2004) 927
14. Prien O. ChemMedChem 1 (2006) 1195
15. Wang Z., Canagarajah B.J., Boehm J.C., Kassisa S., Cobb M.H., Young P.R., Abdel-Meguid S., Adams J.L., and Goldsmith E.J. Structure 6 (1998) 1117
16. Scapin G., Patel S.B., Lisnock J., Becker J.W., and LoGrasso P.V. Chem. Biol. 10 (2003) 705
17. Gill A.L., Frederickson M., Cleasby A., Woodhead S.J., Carr M.G., Woodhead A.J., Walker M.T., Congreve M.S., Devine L.A., Tisi D., O'Reilly M., Seavers L.C.A., Davis D.J., Curry J., Anthony R., Padova A., Murray C.W., Carr R.A.E., and Jhoti H. J. Med. Chem. 48 (2005) 414
18. Wang Z., Harkins P.C., Ulevitch R.J., Han J., Cobb M.H., and Goldsmith E.J. Proc. Natl. Acad. Sci. U.S.A. 94 (1997) 2327
19. Nobeli I., Price S.L., Lommerse J.P.M., and Taylor R. J. Comput. Chem. 18 (1997) 2060
20. Manley P.J., and Bilodeau M.T. Org. Lett. 6 (2004) 2433
21. 4, evaporated, and the product purified by column chromatography to yield 451 mg (42%) of 1 as a white solid.
22. 4, and evaporated. The N- (and O-) alkylated product(s) were purified by flash chromatography.
23. Gerega A., Lapinski L., Nowak M.J., Furmanchuk A., and Leszczynski J. J. Phys. Chem. A 111 (2007) 4934
24. Park K.K., and Lee J.J. Tetrahedron 60 (2004) 2993
25. Larsen, R. D. In Science of Synthesis, 2004, Chapter 15.4.
26. Laufer S., Thuma S., Peifer C., Greim C., Herweh Y., Albrecht A., and Dehner F. Anal. Biochem. (2005) 135
27. Muegge I., and Enyedy I.J. Curr. Med. Chem. 11 (2004) 693